Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness – Four Vaccine Effectiveness Networks, United States, October 2024-February 2025

By sjmartinez • February 28, 2025

Frutos AM, Cleary S, Reeves EL, Ahmad HM, Price AM, Self WH, Zhu Y, Safdar B, Peltan ID, Gibbs KW, Exline MC, Lauring AS, Ball SW, DeSilva M, Tartof SY, Dascomb K, Irving SA, Klein NP, Dixon BE, Ong TC, Vaughn IA, House SL, Faryar KA, Nowalk MP, Gaglani M, Wernli KJ, Murugan V, Williams OL, Selvarangan R, Weinberg GA, Staat MA, Halasa NB, Sahni LC, Michaels MG, Englund JA, Kirby MK, Surie D, Dawood FS, Clopper BR, Moline HL, Link-Gelles R, Payne AB, Harker E, Wielgosz K, Weber ZA, Yang DH, Lewis NM, DeCuir J, Olson SM, Chung JR, Flannery B, Grohskopf LA, Reed C, Garg S, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):83-90. doi: 10.15585/mmwr.mm7406a2. PMID: 40014791.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Core components of male-specific person-centred HIV care: a qualitative analysis from client and healthcare worker perspectives in Malawi

Hubbard J, Mphande M, Robson I, Balakasi K, Phiri K, Chikuse E, Thorp M, Phiri S, Choko AT, Cornell M, Coates T, Dovel K. Core[...]

Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report

Fitzsimmons KC, Fajardo MA, Noor Z. Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a[...]

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, Falchook G, Cleary JM, Kim R, Krishnamurthy A, Marathe O, Youssoufian H, Ellis[...]